HepaHope, Inc.
Successful start of trading for HepaHope, Inc.
HepaHope, Inc. / IPO Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Successful start of trading for HepaHope, Inc. * Shares included in the Entry Standard of the Frankfurt Stock Exchange * First price at EUR 1.68 Frankfurt am Main (Germany), April 30, 2009 - Shares of US-based HepaHope, Inc., a company which is focused on research, development and commercialization of biopharmaceutical products for patients with chronic and acute liver disease, had a successful start of trading at the Frankfurt Stock Exchange today. The first price for the HepaHope share was EUR 1.68, approx. 11% up against the fixed offer price of EUR 1,52 per share. The shares (ISIN: US42689N1090) are included in the Entry Standard (Open Market) of the Frankfurt Stock Exchange. DISCLAIMER No stock exchange or regulatory authority has approved or disapproved of the information contained herein. The securities offered were not registered under the United States Securities Act of 1933 (the '1933 Act') or the securities laws of any state and may not be offered or sold in the United States or to U.S. persons, except pursuant to registration under the 1933 Act or pursuant to an available exemption from such registration requirements. In particular, the securities will be subject to a 'distribution compliance period' of at least one year during which they may not be offered or sold to persons in the United States or U.S. persons except in transactions exempt from registration under the 1933 Act. ABOUT HEPAHOPE HepaHope, Inc. is a biopharmaceutical company focused on research, development and commercialization of biologic products designed to address the needs of patients with liver failure. The Company's leading proprietary technology, the HepaPheresis(TM) System, is based on an Organ Slice Cultivation Technology which aims to maintain the functionality of various organs out of the body (ex vivo) in order to better support liver failure patients. The HepaPheresis(TM) System is currently being prepared for Phase I clinical trials. HepaHope's patented core technology for organ slice cultivation is also the foundation of other product candidates in the pipeline of this company in the oncology testing market and the drug development market. The members of the management and science advisory board of the company represent leading scientists in liver research. HepaHope was founded in February 1999. The offices and research facilities of the US Company are both located in California. For further information please visit: www.hepahope.com FOR MEDIA INQUIRIES HepaHope, Inc. Bhavesh Singh Chief Financial Officer P + 1 949 421 3617 M + 1 201 920 1819 Investor Relations IR.on AG Achim Josten Dariusch Manssuri T +49 221. 9140.970 F +49 221. 9140.978 E-mail: info@ir-on.com 30.04.2009 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: HepaHope, Inc. 30 Fairbanks, Suite 110 CA 92618 Irvin Vereinigte Staaten von Amerika Phone: 001 9494213600 Fax: 001 9494213680 E-mail: investor@hepahope.com Internet: http://www.hepahope.com ISIN: US42689N1090, USU425541021 WKN: A0RMY4, A0RLC1 Listed: Open Market (Entry Standard) in Frankfurt Notierung vorgesehen / designated to be listed End of News DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden